Analysis of the effectiveness and safety of leazuzumab in treatment of neovascular glaucoma
Objective To investigate the efficacy and safety of leazuzumab combined with EX-PRESS glaucoma drainage in the treatment of neovascular glaucoma (NVG). Methods 60 patients (74 eyes) with NVG were divided into two groups. The control group was treated by bevacizumab combined with surgery. The observation group was treated by leazuzumab combined with surgery. The intraocular pressure, the number of anti-glaucoma medication and revascularization of revascularization of iris surface were observed before and after operation. Results Compared with the control group, the extinction time of regression of neovascularization in the observation group was significantly shorter, and rate of complete regression of neovascularization was significantly higher after treatment; the intraocular pressure of the two groups was significantly lower within one year after surgery, the number of anti-glaucoma medication was significantly reduced, and the intraocular pressure of the observation group was significantly higher than that in the control group within seven days after surgery (P<0.05). Conclusion Leazuzumab combined with EX-PRESS glaucoma drainage implantation can effectively promote the neonatal blood vessels to completely dissipate, and is better than bevacizumab in short-term reduction of intraocular pressure.
NETL
NSTL
万方数据
维普
